Skip to main content
. 2011 Jan;8(1):29–35.

Table 4.

Percent of subjects experiencing adverse events reported by treatment group

DRUG GROUP HEAD, EYES, EARS, NOSE, AND THROAT MUSCULO/SKELETAL GENITO-URINARY PULMONARY PSYCHIATRIC NEUROLOGICAL (FAINTING, DIZZINESS, HEADACHES) GASTRO-INTESTINAL OTHER
Quetiapine n=15 33.30% 6.70% 6.70% 13.30% 46.70% 17.30% 26.70% 0.93%
Divalproex ER n=13 7.70% 7.70% 7.70% 15.40% 30.80% 38.50% 30.80% 1.38%